Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemia

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  1994-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF01519980PMID 7987859PMCID PMC11038187
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

  1994cited by this paper
• Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

  1994cited by this paper
• Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

  1993cited by this paper
• Circulating PTHrP concentrations in tumor‐induced hypercalcemia: Influence on the response to bisphosphonate and changes after therapy

  1993influential reference
• Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.

  1993cited by this paper
• Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma.

  1993cited by this paper
• Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis.

  1993cited by this paper
• Bone destruction in cancer.

  1993cited by this paper
• Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy

  1993cited by this paper
• Bone destruction in cancer.

  1993cited by this paper
• Recovery of parathyroid hormone secretion during correction of tumor-associated hypercalcemia.

  1992influential reference
• Bone metastases and tumor‐induced hypercalcemia

  1992cited by this paper
• Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.

  1992influential reference
• Interleukin-6 serum level and monocyte production in head and neck cancer.

  1992cited by this paper
• Perspectives: Interleukin‐6: An osteotropic factor?

  1992cited by this paper
• Interleukin-6: an osteotropic factor?

  1992cited by this paper
• Parathyroid hormone-related protein: structure, function, and measurement.

  1992cited by this paper
• The role of cytokines in the regulation of local bone resorption.

  1991cited by this paper
• Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells.

  1991cited by this paper
• Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer.

  1991cited by this paper
• Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

  1991influential reference
• Pheochromocytoma with pyrexia and marked inflammatory signs: a paraneoplastic syndrome with possible relation to interleukin-6 production.

  1991cited by this paper
• Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice.

  1991cited by this paper
• High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.

  1991cited by this paper
• IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release.

  1990cited by this paper
• Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures.

  1990cited by this paper
• Interleukin-6: an overview.

  1990cited by this paper
• Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

  1989cited by this paper
• Interleukin-6 immunoreactivity in human tumors.

  1989cited by this paper
• Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomas

  1989cited by this paper
• Increased plasma levels of interleukin-6 in sepsis.

  1989cited by this paper
• Increased plasma levels of interleukin-6 in sepsis [see comments]

  1989cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

  1986cited by this paper
• Serum osteocalcin (BGP) in tumor‐associated hypercalcemia

  1986influential reference

• Animal Models of Cancer-Associated Hypercalcemia

  2017cites this paper
• Parathyroid hormone related protein (PTHrP) in tumor progression.

  2011cites this paper
• Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma

  2011cites this paper
• Pathogenesis and treatments of humoral hypercalcemia of malignancy in adult T -cell leukemia /lymphoma induced by human T -lymphotropic virus type 1

  2009cites this paper
• Relationship of plasma bone cytokines with hypercalcemia in cancer patients.

  2000cites this paper
• Cytokines and advanced cancer.

  2000cites this paper
• The role of cytokines in cancer cachexia

  1999cites this paper
• Regulation of Interleukin‐6 Secretion from Mononuclear Blood Cells by Extracellular Calcium

  1997cites this paper
• Association between preoperative acute phase response and postoperative complications.

  1997cites this paper
• Humoral Hypercalcemia of Malignancy with Elevated Plasma PTHrP, TNFα and IL‐6 in Cutaneous Squamous Cell Carcinoma

  1996cites this paper
• A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.

  1996cites this paper
• Chlovalicin, a new cytocidal antibiotic produced by Sporothrix sp. FO-4649. I. Taxonomy, fermentation, isolation and biological activities.

  1996cites this paper